Islet inflammation in type 2 diabetes: from metabolic stress to therapy.
about
Hyaluronan: A Mediator of Islet Dysfunction and Destruction in Diabetes?Molecular Events Linking Oxidative Stress and Inflammation to Insulin Resistance and β-Cell DysfunctionPotential roles of GPR120 and its agonists in the management of diabetesRole of microRNAs in islet beta-cell compensation and failure during diabetesThe Beta Cell in Its Cluster: Stochastic Graphs of Beta Cell Connectivity in the Islets of LangerhansAssociation of dioxin and other persistent organic pollutants (POPs) with diabetes: epidemiological evidence and new mechanisms of beta cell dysfunctionSilencing mitogen-activated protein 4 kinase 4 (MAP4K4) protects beta cells from tumor necrosis factor-alpha-induced decrease of IRS-2 and inhibition of glucose-stimulated insulin secretionAn Islet-Targeted Genome-Wide Association Scan Identifies Novel Genes Implicated in Cytokine-Mediated Islet Stress in Type 2 Diabetes.Circulating levels of IL-1B+IL-6 cause ER stress and dysfunction in islets from prediabetic male mice.A novel fluorescence imaging approach for comparative measurements of pancreatic islet function in vitro.Evidence that low-grade systemic inflammation can induce islet dysfunction as measured by impaired calcium handling.12-Lipoxygenase Products Reduce Insulin Secretion and {beta}-Cell Viability in Human IsletsAdenosine through the A2A adenosine receptor increases IL-1β in the brain contributing to anxietyT cells cooperate with palmitic acid in induction of beta cell apoptosis.Islet endothelial activation and oxidative stress gene expression is reduced by IL-1Ra treatment in the type 2 diabetic GK ratDefining and characterizing the progression of type 2 diabetes.Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study.Activation of distinct P2Y receptor subtypes stimulates insulin secretion in MIN6 mouse pancreatic beta cells.Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes.Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity.Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)Baseline serum 25-hydroxy vitamin D in predicting glycemic status and insulin levels.An overview of the identification and management of the metabolic syndrome in chiropractic practice.Identification of autoantibody-negative autoimmune type 2 diabetic patients.A gender-centered ecological framework targeting Black men living with diabetes: integrating a "masculinity" perspective in diabetes management and education research.Progression from high insulin resistance to type 2 diabetes does not entail additional visceral adipose tissue inflammation.CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis.Calcineurin/nuclear factor of activated T cells and MAPK signaling induce TNF-{alpha} gene expression in pancreatic islet endocrine cells.Decreased serum CA19-9 is associated with improvement of insulin resistance and metabolic control in patients with obesity and type 2 diabetes after Roux-en-Y gastric bypass.Impact of islet autoimmunity on the progressive β-cell functional decline in type 2 diabetes.Sustained delivery of IL-1Ra from PF127-gel reduces hyperglycemia in diabetic GK-rats.Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.Effects of insulin versus sulphonylurea on beta-cell secretion in recently diagnosed type 2 diabetes patients: a 6-year follow-up study.Bimodal effect on pancreatic β-cells of secretory products from normal or insulin-resistant human skeletal muscleThe glial glutamate transporter 1 (GLT1) is expressed by pancreatic beta-cells and prevents glutamate-induced beta-cell deathProstatic fibrosis, lower urinary tract symptoms, and BPHNeutralizing interleukin-1beta (IL-1beta) induces beta-cell survival by maintaining PDX1 protein nuclear localization.The class I histone deacetylase inhibitor MS-275 prevents pancreatic beta cell death induced by palmitate.Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell massPericytopathy: oxidative stress and impaired cellular longevity in the pancreas and skeletal muscle in metabolic syndrome and type 2 diabetes.
P2860
Q26799151-89166D7F-30F8-4954-8AC9-AF758B0CE589Q26800081-381FF829-EAEF-4EC7-B4F9-ED30BD9D1A37Q26827101-D5AE9EA0-BE35-4200-A813-ECFF005DE0BEQ26995308-0B6F68CC-66E7-482B-893B-313EC63CB84EQ27318143-90E3F986-A8DC-4575-98F5-FCDA7BB4B1CCQ28387870-2615D468-8B65-4528-86C1-59E0029CD1CEQ28582459-3212DE73-7149-45A4-A47F-5ECB0CCE9B93Q30279270-FECD7286-AD57-4B9A-8023-407B4BC5B3EEQ30410968-BB0DD3B2-2C78-4F84-A2EE-F87F77ADBEA9Q30429083-9957E94E-69C1-40EB-AF97-F7B0A94511CBQ30430981-20F05B4B-0132-4FF6-ABA8-07838F332A78Q30433351-B6ABF271-3E0C-47B8-95E6-F5FC0A087B94Q30587153-7B50CB6C-2793-4C15-B985-BA094AB527F0Q33451028-E932A5F0-FEDF-4466-8EF8-9B064EDFF8EAQ33501717-36F635E0-D36A-4092-8E68-460D71B930A3Q33610728-C2CE446F-28B8-4CF2-9E00-1FD27E5F530FQ33803480-7B1688EC-9DA6-40CA-9B2F-81C0865C1056Q33828185-86677B23-A86C-40B5-B176-F27B89A6FC20Q33844872-D4EAA85E-C88F-4496-BF12-AB7C3DF29B57Q33967100-B8C82778-633B-4D83-A6A0-6587F6D24CF0Q34003019-7EAF7932-EDE2-4CA1-A6D3-DE9383B2C0B8Q34167403-063AA910-99AD-44D0-A583-3DA81F66C385Q34168107-0DBD80A2-DCDE-44EC-A136-083C5BC78F79Q34419575-85535727-7D2F-4DF5-AF25-219C070E7487Q34450887-00B9879B-6430-4846-B5EF-9F5AE78B5BB4Q34461002-37C57325-2A68-40DB-95FA-B37A98D15180Q34485215-79E51064-EAB1-4B1C-AA41-52AFBD6AF2E5Q34488816-95A366FA-5DD8-4ED6-AD19-F916375936B5Q34523725-BD2E0465-C058-4E76-8DEB-75A0E7604B10Q34545320-4FC721BF-DFED-46F9-A319-BEE84CB46276Q34586474-1D6AF859-D5BF-4F73-95E4-AC2369D4C1A3Q34597496-B3243965-AE84-4E17-9FC0-06027943E467Q34703169-93E12F5F-E058-4BE7-975D-7F6B44305D3DQ34718673-2FEDC238-CFC7-4E56-8018-9C7302A25AB3Q34800004-D518D9F3-DB11-40D7-B9C6-EFAF9CBEA6C5Q34822091-931F00D6-FB31-4609-9F44-8573C6F40AAFQ34948047-EF49312F-1FCC-43DA-ABF1-AF25131E61D4Q34956310-1304AC0C-ECFE-40C4-8AA1-CA0D3320BA98Q35055522-40043C63-B9E2-4CAD-9D9D-A802F484DABAQ35157945-045BB7CA-F7D8-487B-BC6F-61AA099CD614
P2860
Islet inflammation in type 2 diabetes: from metabolic stress to therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Islet inflammation in type 2 diabetes: from metabolic stress to therapy.
@en
Islet inflammation in type 2 diabetes: from metabolic stress to therapy.
@nl
type
label
Islet inflammation in type 2 diabetes: from metabolic stress to therapy.
@en
Islet inflammation in type 2 diabetes: from metabolic stress to therapy.
@nl
prefLabel
Islet inflammation in type 2 diabetes: from metabolic stress to therapy.
@en
Islet inflammation in type 2 diabetes: from metabolic stress to therapy.
@nl
P2093
P50
P356
P1433
P1476
Islet inflammation in type 2 diabetes: from metabolic stress to therapy
@en
P2093
Helga Ellingsgaard
Marc Y Donath
Mirjam Faulenbach
P304
P356
10.2337/DC08-S243
P407
P433
Supplement 2
P478
31 Suppl 2
P577
2008-02-01T00:00:00Z